Highest-materiality recent filing
Entered into Sales Agreement with TD Securities (USA) LLC for at-the-market offering of up to $250M of common stock.
Anteris appoints Susan Knight and Stephen Denaro to board of directors
Ms. Knight appointed as Class I Director with term expiring at 2028 annual meeting; joins Audit & Risk Committee.
Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US
Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.
Anteris terminates v2v development deal, pays $400K break fee
Notified v2vmedtech of discontinuation of development contributions after Stage 1 completion.
Anteris Technologies signs 11-year lease for 181,436 sq ft in Brooklyn Park, MN
Lease executed April 23, 2026; initial term from Sept 1, 2026 to Aug 31, 2037.
Anteris Technologies grants CFO Matthew McDonnell $500K in RSUs vesting over three years
Compensation Committee approved RSU grant to CFO Matthew McDonnell valued at $500,000, effective March 4, 2026.
Anteris reports FY2025 revenue down 29%, net loss widens to $94M; starts PARADIGM trial
FY2025 revenue $1.9M (-29% YoY); net loss $94.1M (23% wider); cash used in ops $77.8M.
Anteris raises ~$320M via public offering and Medtronic PIPE for DurAVR THV trial
Public offering of 40M shares at $5.75 (including full over-allotment); gross proceeds ~$230M.
Medtronic makes $90M strategic investment in Anteris; combined $320M capital raise
Medtronic invested $90M in Anteris via stock purchase; Anteris also completed an underwritten common stock offering for total gross proceeds of $320M.
Director Stephen Denaro resigns from Anteris Technologies Board effective Dec 13, 2025
Stephen Denaro resigned from the Board of Directors as a Class II director, effective December 13, 2025.
Anteris Technologies Global Corp. Reports Results of 2025 Annual Meeting of Stockholders
Stockholders elected John Seaberg and Gregory Moss as Class I directors with 14,305,918 and 15,653,027 votes for, respectively.
Anteris Technologies not renewing supply agreement with 4C Medical for ADAPT tissue
On Nov 26, 2025, Anteris notified 4C Medical of non-renewal of Second Amended Supply and License Agreement.
Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients
No valve-related mortality and no moderate/severe paravalvular leak at 30 days.
Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US
FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.
Anteris obtains FDA approval to initiate PARADIGM pivotal trial for DurAVR THV
FDA approved global IDE trial for DurAVR THV in severe aortic stenosis patients.
Anteris enrolls & treats first patients in DurAVR THV global pivotal trial
First patients enrolled and successfully treated in PARADIGM Trial for DurAVR THV in severe calcific aortic stenosis.
Anteris Technologies closes $11.5M common stock and warrant offering
Sold 2,346,936 shares and 5-year warrants at $4.90/unit; gross proceeds ~$11.5M.
Anteris Technologies raises ~$25M via unregistered placement of shares, CDIs, and warrants
Sold 2,244,896 shares at $4.90/share with 5-year warrants at $7.50; 2,788,064 CDIs at A$7.50 with warrants at A$11.50.
Anteris gets Danish clearance to start DurAVR THV global pivotal trial
Danish Medicines Agency clears Anteris to initiate DurAVR THV PARADIGM Trial for severe calcific aortic stenosis.
Anteris sets first annual meeting for Dec 3, 2025; proposal deadline Oct 25
Annual Meeting of Stockholders scheduled for December 3, 2025 (Dec 4 in Australia).
Anteris delays PARADIGM pivotal trial enrollment to Q4 2025 after FDA request
Patient enrollment in PARADIGM trial now expected Q4 2025, previously Q3 2025.
Anteris Technologies adjourns special meeting to Sept 29 due to insufficient quorum
Special meeting of Sept 18, 2025 adjourned without business due to lack of required quorum.
Anteris postpones special stockholder meeting to Sept 18 for broader participation
Special meeting postponed from Sept 11 to Sept 18, 2025; record date unchanged (Aug 11, 2025).
Anteris Technologies postpones Special Meeting to Sept 11 for broader stockholder voting
Meeting postponed from Sept 4 to Sept 11, 2025; record date Aug 11 unchanged.
Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants
Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.
Anteris Technologies gets ASX waiver from Listing Rule 7.1 on securities issuance
ASX granted waiver from Listing Rule 7.1, allowing above-15% issuance without stockholder approval.
Anteris Technologies enters amended master services agreement with Switchback Medical
Agreement covers development, manufacturing, engineering, and testing services at set prices per unit.
Anteris appoints Gregory Moss and David Roberts to board; Wenyi Gu resigns
Gregory Moss appointed Class I Director, term expiring at 2025 annual meeting; serves on Nominating Committee.
Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted
Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.
Anteris reaches 100 patients treated with DurAVR THV; strong one-year safety and efficacy data
Over 100 patients treated with DurAVR THV, including de novo, valve-in-valve, and bicuspid cases.
Anteris DurAVR THV reports zero PPM at one year in small annuli patients
One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).
Anteris Technologies posts FY2024 net loss of $76M; auditor flags going concern doubt
Net loss after tax $76.0M vs $46.8M in 2023; revenue flat at $2.7M.
Anteris Technologies appoints David St Denis as President and Class II director
Appointment effective March 5, 2025; St Denis retains COO role and serves as CEO of v2vmedtech.
Anteris Technologies partial exercise of IPO over-allotment option for 78,481 shares at $6.00
Underwriters partially exercised over-allotment option for 78,481 shares at $6.00 per share (less $0.42 discount).
Anteris receives Obsidian redemption notice for convertible notes; owes ~$5.89M cash
Obsidian required redemption of all convertible notes after IPO and reorganization close on Dec 16, 2024.
Anteris closes IPO raising $80M net; completes reorganization with ATL
IPO of 14.8M shares at $6.00/sh closed Dec 16, 2024; net proceeds $80.0M.
On May 11, 2026 (May 12, 2026 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board.
On May 11, 2026 (May 12, 2026 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board.
Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board.
Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.
On March 5, 2025 (March 6, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately.
On March 5, 2025 (March 6, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately.
Max materiality 0.95 · Median 0.62 · Most common event other_material